Trial Profile
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Apilimod dimesylate (Primary) ; Atezolizumab; Rituximab; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors AI Therapeutics; OrphAI Therapeutics
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 02 May 2022 Status changed from completed to active, no longer recruiting.
- 17 Dec 2021 Status changed from active, no longer recruiting to completed.